Phenotype distribution of the paraoxonase gene in patients with cardiac disease

Abstract

IntroductionParaoxonase (PON1) is an enigmatic enzyme with multiple enzymatic properties including arylesterase and lactonase activities besides its ability to hydrolyze the toxic metabolite of parathion, paraoxon. The aim of this study was to determine the phenotype distribution of PON1 in patients with cardiac disease who were classified in coronary artery bypass grafting (CABG), heart valve disease (HVD), heart failure (HF) and ST elevation myocardial infarction (STEMI) groups and healthy subjects as a control group.Material and methodsA total of 300 people (100 cardiac surgery (70 CABG and 30 HVD), 70 HF, 30 STEMI patients and 100 healthy controls) were admitted to this study. Individual variations in PON1 were determined using the dual substrate (paraoxon and phenylacetate) method.ResultsThe following phenotype distributions were found in the cardiac disease and control groups: cardiac disease group (n = 200): 48.5% (QQ), 42.5% (QR), 9% (RR) and control group (n = 100): 58% (QQ), 39% (QR), 3% (RR). RR (high activity) phenotypic distribution was more common in the cardiac disease group than in controls (p = 0.04). In particular, the frequency of the RR phenotype was two- to three-fold higher in the STEMI and HF patients compared to the controls as well as CABG and HVD groups.ConclusionsWe found a higher percentage of RR phenotype in STEMI and HF patients compared to a large control group as well as compared to two other groups of cardiac disease patients.

The relationship between serum ferritin levels and serum lipids and HDL function with respect to age and gender

“…On the other hand, it has been recently ac knowledged that HDL functionality is more critical than its concentration [19,42,43]. PON1 and ARE, which are important indicators of HDL function, are multifunctional enzymes that have antioxidant, antiatherogenic, lactonase and homocysteinethio lactonase activities [44,45]. In our smaller group of 100 individuals, although there was a negative correlation between HDLC and SFer levels, there was no correlation between SFer levels and PON1 or ARE activities.…”

Renin-angiotensin system inhibitor attenuates oxidative stress induced human coronary artery endothelial cell dysfunction via the PI3K/AKT/mTOR pathway

“…Endothelial dysfunction is an early feature of atherosclerosis and cardiovascular disease [1, 2]. The protection of endothelial function can prevent the development of cardiovascular disease [3, 4]. Endothelial dysfunction leads to several pathological conditions such as impairment of the anti-inflammatory properties of the endothelium, impaired modulation of vascular growth, and dysregulation of vascular remodeling [5].…”